IMAT-HCC model: Liver stiffness–enhanced integrated risk stratification for HCC recurrence after resection

Background & Aims: Early enthusiasm for adjuvant immunotherapy with atezolizumab plus bevacizumab after curative treatment of hepatocellular carcinoma (HCC) has been tempered by longer follow-up, which questioned the durability of benefit. Beyond treatment efficacy, inadequate patient selection...

Descripció completa

Dades bibliogràfiques

Autors principals:	Matteo Serenari, Matteo Cescon, Chiara Bonatti, Bernardo Stefanini, Edoardo Prosperi, Elton Dajti, Francesco Tovoli, Matteo Ravaioli, Fabio Piscaglia, Federico Ravaioli
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2026-06-01
Col·lecció:	JHEP Reports
Matèries:	Hepatectomy Hepatocellular carcinoma Liver stiffness Neoadjuvant therapy
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2589555926000960
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!